Evidence map›Paper›PMID 36082663›Full record

Trial reportCirculation2022

Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.

Amil M Shah, Brian Claggett, Narayana Prasad, Guichu Li, Mayra Volquez, Karola Jering, Maja Cikes, Attila Kovacs, Wilfried Mullens, Jose C Nicolau and 8 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02924727 (A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction), which is not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02924727 phase3completednot on this map

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction (AMI)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2016 to 2021Enrolled5,669ConditionsAcute Myocardial InfarctionArmsLCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. The use of sacubitril/valsartan in different forms of heart failure.International journal of cardiology. Heart & vasculature · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 9 countries.

Amil M ShahDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0003-1056-4451
Brian ClaggettDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0002-4215-9218
Narayana PrasadDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0002-6280-2741
Guichu LiDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0002-3690-9721
Mayra VolquezDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).
Karola JeringDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0002-5243-1959
Maja CikesUniversity of Zagreb School of Medicine and University Hospital Centre Zagreb, Croatia (M.C.).ORCID 0000-0002-4772-5549
Attila KovacsHeart and Vascular Center, Semmelweis University, Budapest, Hungary (A.K.).ORCID 0000-0003-2320-6434
Wilfried MullensUniversity Hasselt, Ziekenhuis Oost Limburg, Genk, Belgium (W.M.).
Jose C NicolauInstituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Brazil (J.C.N.).ORCID 0000-0002-9680-3689
Lars KøberRigshospitalet, Copenhagen, Denmark (L.K.).ORCID 0000-0002-6635-1466
Peter van der MeerUniversity of Groningen, The Netherlands (P.v.d.M.).ORCID 0000-0002-9705-4413
Pardeep S JhundUniversity of Glasgow, Scotland (P.S.J.).ORCID 0000-0003-4306-5317
Ghionul IbramNovartis Pharmaceutical Corporation, East Hanover, NJ (G.I., M.L., Y.Z.).
Martin LefkowitzNovartis Pharmaceutical Corporation, East Hanover, NJ (G.I., M.L., Y.Z.).
Yinong ZhouNovartis Pharmaceutical Corporation, East Hanover, NJ (G.I., M.L., Y.Z.).
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0003-3698-9597
Marc A PfefferDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., N.P., G.L., M.V., K.J., S.D.S, M.A.P.).ORCID 0000-0003-3876-7568
Brigham and Women's Hospital · USNovartis (Switzerland) · CHHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRRigshospitalet · DKSemmelweis University · HUUniversity Hospital Centre Zagreb · HRUniversity of Glasgow · GBUniversity of Groningen · NLZiekenhuis Oost-Limburg · BE

Funding

Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5M
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1M
Quantifying cardiac structure and function to define the progression to hear failure in African AmericansR01HL143224 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2018 to 2021
$3.4M
Proteomic signatures to identifypathways underlying the progression toheart failureR01HL148218 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M, YU, BING · 2020 to 2023
$3.4M
Contributions of pulmonary arterial and venous remodeling to HFpEF in the elderlyR01HL160025 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SAN JOSE ESTEPAR, RAUL, SHAH, AMIL M · 2022 to 2025
$3.0M
Mentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608k
NHLBI NIH HHS K24 HL152008NHLBI NIH HHS R01 HL135008NHLBI NIH HHS R01 HL143224NHLBI NIH HHS R01 HL148218NHLBI NIH HHS R01 HL150342NHLBI NIH HHS R01 HL160025
6 · The paper itself

Abstract

backgroundAngiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI.

methodsIn a prespecified substudy, 544 PARADISE-MI participants were enrolled in the Echo Study to undergo protocol echocardiography at randomization and after 8 months. Patients were randomized within 0.5 to 7 days of presentation with their index AMI to receive a target dose of sacubitril/valsartan 200 mg or ramipril 5 mg twice daily. Echocardiographic measures were performed at a core laboratory by investigators blinded to treatment assignment. The effect of treatment on change in echo measures was assessed with ANCOVA with adjustment for baseline value and enrollment region. The primary end points were change in LV ejection fraction (LVEF) and left atrial volume (LAV), and prespecified secondary end points included changes in LV end-diastolic and end-systolic volumes.

resultsMean age was 64±12 years; 26% were women; mean LVEF was 42±12%; and LAV was 49±17 mL. Of 544 enrolled patients, 457 (84%) had a follow-up echo at 8 months (228 taking sacubitril/valsartan, 229 taking ramipril). There was no significant difference in change in LVEF (

conclusionsTreatment with sacubitril/valsartan compared with ramipril after AMI did not result in changes in LVEF or LAV at 8 months. Patients randomized to sacubitril/valsartan had less LV enlargement and greater improvement in filling pressure. Measures of LV size, systolic function, and diastolic properties were predictive of cardiovascular death and incident heart failure after AMI in this contemporary, well-treated cohort. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02924727.

Indexed as

Heart FailureMyocardial InfarctionAgedAminobutyratesAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsEchocardiographyFemaleHumansHypertrophy, Left VentricularMaleMiddle AgedNeprilysinProspective StudiesRamiprilAminobutyratesAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsNeprilysinRamiprilReceptors, AngiotensinsacubitrilTetrazolesValsartanechocardiographyheart failuremyocardial infarction

Identifiers

PMID36082663
PMCPMC9529950
OpenAlexW4295088390

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.